{"id":"W4386102828","doi":"10.1016/s0140-6736(23)01245-x","title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":427,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"MacroGenics; Puma Biotechnology; Mylan; Gilead Sciences; Amgen; Pfizer; Samsung; Genentech; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Metastatic breast cancer; Internal medicine; Oncology; Clinical endpoint; Breast cancer; Hazard ratio; Taxane; Cancer; Clinical trial; Confidence interval","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05675231104043848,"score_gpt":0.3583262430471858,"score_spread":0.3015739320067473,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}